Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIXC NASDAQ:BCTX NASDAQ:BDRX NASDAQ:NRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.38+7.0%$1.32$0.92▼$8.81$26.10M0.5239,529 shs100,185 shsBCTXBriacell Therap$3.72-4.1%$4.12$2.98▼$36.90$28.13M1.26235,786 shs181,181 shsBDRXBiodexa Pharmaceuticals$3.24+4.2%$3.62$2.86▼$96.50$6.21M1.15980,846 shs13,673 shsNRSNNeuroSense Therapeutics$0.77-4.6%$0.78$0.63▼$2.60$26.37M1.6154,390 shs44,638 shs7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics+6.98%+2.22%-2.13%+11.29%+137,999,900.00%BCTXBriacell Therap-4.12%-8.15%-6.77%-5.10%-89.52%BDRXBiodexa Pharmaceuticals+4.18%-4.71%-19.00%-44.14%-95.02%NRSNNeuroSense Therapeutics-4.56%-9.16%+12.03%-14.49%-48.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.38+7.0%$1.32$0.92▼$8.81$26.10M0.5239,529 shs100,185 shsBCTXBriacell Therap$3.72-4.1%$4.12$2.98▼$36.90$28.13M1.26235,786 shs181,181 shsBDRXBiodexa Pharmaceuticals$3.24+4.2%$3.62$2.86▼$96.50$6.21M1.15980,846 shs13,673 shsNRSNNeuroSense Therapeutics$0.77-4.6%$0.78$0.63▼$2.60$26.37M1.6154,390 shs44,638 shs7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics+6.98%+2.22%-2.13%+11.29%+137,999,900.00%BCTXBriacell Therap-4.12%-8.15%-6.77%-5.10%-89.52%BDRXBiodexa Pharmaceuticals+4.18%-4.71%-19.00%-44.14%-95.02%NRSNNeuroSense Therapeutics-4.56%-9.16%+12.03%-14.49%-48.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIXCQualigen Therapeutics 1.00SellN/AN/ABCTXBriacell Therap 1.00SellN/AN/ABDRXBiodexa Pharmaceuticals 1.00SellN/AN/ANRSNNeuroSense Therapeutics 2.60Moderate Buy$8.50999.61% UpsideCurrent Analyst Ratings BreakdownLatest BDRX, NRSN, AIXC, and BCTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/8/2026NRSNNeuroSense Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/29/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/24/2026AIXCQualigen Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BCTXBriacell Therap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/25/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/17/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/10/2026NRSNNeuroSense Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.003/9/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIXCQualigen TherapeuticsN/AN/AN/AN/A$0.81 per shareN/ABCTXBriacell TherapN/AN/AN/AN/A$9.20 per shareN/ABDRXBiodexa Pharmaceuticals$470K13.79N/AN/A$110.30 per share0.03NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.05) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIXCQualigen Therapeutics-$16.97M-$6.47N/AN/AN/AN/A-771.52%-79.52%N/ABCTXBriacell Therap-$26.31M-$23.33N/AN/AN/AN/A-173.08%-139.64%N/ABDRXBiodexa Pharmaceuticals-$8.42MN/AN/AN/AN/AN/AN/AN/AN/ANRSNNeuroSense Therapeutics-$11.12M-$0.54N/AN/AN/AN/AN/AN/A6/22/2026 (Estimated)Latest BDRX, NRSN, AIXC, and BCTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026AIXCQualigen TherapeuticsN/A-$0.79N/A-$0.79N/AN/A3/30/2026Q4 2025AIXCQualigen TherapeuticsN/A-$3.76N/A-$3.76N/AN/A3/27/2026Q4 2025BDRXBiodexa Pharmaceuticals-$0.0066$3.5250+$3.5316-$5.35N/AN/A3/10/2026Q2 2026BCTXBriacell TherapN/A-$2.58N/A-$2.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIXCQualigen TherapeuticsN/AN/AN/AN/AN/ABCTXBriacell TherapN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIXCQualigen TherapeuticsN/A11.5711.57BCTXBriacell TherapN/A10.1010.10BDRXBiodexa PharmaceuticalsN/A2.032.03NRSNNeuroSense TherapeuticsN/A0.310.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIXCQualigen Therapeutics3.18%BCTXBriacell Therap15.42%BDRXBiodexa Pharmaceuticals17.51%NRSNNeuroSense Therapeutics1.04%Insider OwnershipCompanyInsider OwnershipAIXCQualigen Therapeutics1.17%BCTXBriacell Therap0.74%BDRXBiodexa Pharmaceuticals0.34%NRSNNeuroSense Therapeutics27.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIXCQualigen Therapeutics5020.24 million20.00 millionN/ABCTXBriacell Therap87.25 million7.20 millionNo DataBDRXBiodexa Pharmaceuticals202.00 million1.99 millionNot OptionableNRSNNeuroSense Therapeutics1032.56 million23.64 millionNot OptionableBDRX, NRSN, AIXC, and BCTX HeadlinesRecent News About These CompaniesNRSN Share News TodayMay 19 at 1:10 PM | uk.investing.comNeuroSense Secures Insider-Led $600,000 PIPE at Premium Share PriceApril 28, 2026 | tipranks.comNeuroSense Announces Pricing of Insider-Led PIPE FinancingApril 28, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Opus Genetics (IRD)April 9, 2026 | theglobeandmail.comNeuroSense Granted Brazilian Patent Covering PrimeC CompositionApril 6, 2026 | prnewswire.comNeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value RequirementsApril 3, 2026 | prnewswire.comNeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business UpdateMarch 31, 2026 | prnewswire.comNeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's ReadoutMarch 24, 2026 | prnewswire.comPrimeC New Data to Be Presented at AD/PD™ 2026 ConferenceMarch 18, 2026 | prnewswire.comNeuroSense: JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological ActivityMarch 16, 2026 | finanznachrichten.deJAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological ActivityMarch 16, 2026 | prnewswire.comRoth Capital initiates coverage of NeuroSense Therapeutics (NRSN) with buy recommendationMarch 11, 2026 | msn.comPrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific ConferenceMarch 9, 2026 | prnewswire.comNeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 14.7% – Time to Sell?February 19, 2026 | defenseworld.netDNeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALSFebruary 18, 2026 | prnewswire.comNeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital IncreaseFebruary 13, 2026 | tipranks.comNeurosense Therapeutics stock rises after securing Australian patent for PrimeCFebruary 11, 2026 | au.investing.comNeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC CompositionFebruary 9, 2026 | prnewswire.comNeuroSense Granted U.S. Patent for Treatment of Alzheimer's DiseaseJanuary 21, 2026 | prnewswire.comNeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve CashJanuary 17, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDRX, NRSN, AIXC, and BCTX Company DescriptionsQualigen Therapeutics NASDAQ:AIXC$1.38 +0.09 (+6.98%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$1.24 -0.14 (-10.43%) As of 06:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Briacell Therap NASDAQ:BCTX$3.72 -0.16 (-4.12%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$3.59 -0.13 (-3.39%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Biodexa Pharmaceuticals NASDAQ:BDRX$3.24 +0.13 (+4.18%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$3.18 -0.06 (-1.85%) As of 07:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.NeuroSense Therapeutics NASDAQ:NRSN$0.77 -0.04 (-4.56%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$0.77 0.00 (-0.39%) As of 07:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
